Actualización del coste de vacunar a lo largo de toda la vida en España para el año 2023 / Updated cost of vaccinating throughout life in Spain in 2023

Fundamentos: en el calendario de vacunación a lo largo de toda la vida del consejo interterritorial del sistema nacional de Salud (cisns) se introdujeron cuatro modificaciones importantes en 2023. El objetivo de este estudio fue estimar el coste de la vacuNación a lo largo de toda la vida a una persona sana y a ciertos grupos de riesgo tomando como referencia el calendario de 2023 yCompararlo con una estimación previa de 2019. Métodos: se realizo un estudio descriptivo del coste de administrar las vacunas incluidas en el calendario de vacunación a lo Largo de toda la vida para el año 2023 y en el calendario para grupos de riesgo.Resultados: el coste estimado de vacunar a una persona sana a lo largo de toda la vida en 2023 es de 1.541,56 euros en mujeres Y 1.498,18 euros en hombres, lo que supondría un incremento del 125% con respecto al coste en 2019. Las condiciones de riesgo con El coste más alto son asplenia además de déficit del complemento e inmunodeficiencias primarias, suponiendo 3.159.82 euros y 2.566Euros, respectivamente, de media. Vacunar a toda la población sana en españa en un año costaría unos 565 millones de euros y Vacunar a la cohorte de recién nacidos de 2023 a lo largo de toda la vida unos 500 millones de euros.Conclusiones: a pesar del incremento en el coste en 2023, considerando el impacto económico de las enfermedades prevenibles por vacunación en la sociedad, la vacunación sigue siendo una intervención barata que aporta múltiples beneficios.(AU)

Background: four modifications were introduced in the lifetime vaccination schedule of the interterritorial council of the National health system (cisns) in 2023. the aim of this study was to estimate the cost of vaccinating a healthy person and people with Certain risk conditions throughout life in spain and to compare with a previous estimation from 2019.Methods: a descriptive study of the cost of administering the vaccines included in the lifetime vaccination schedule for the year 2023 and in the schedule for risk groups was carried out. Results: the estimated cost to immunize a healthy person throughout life in 2023 is 1,541.56€ for a woman and 1,498.18€ for a Men, which corresponds to an increase of 125% compared to the cost in 2019. The risk conditions with the highest cost are asplenia And complement deficiency and primary immunodeficiencies, with a cost of 3,159.82 euros and 2,566 euros respectively on average. The cost of vaccinating the whole healthy population in spain in a year is around 565m€. Moreover, the cost of vaccinating the New-borns cohort of 2023 was estimated at 500m€. Conclusions: despite the cost increase in 2023, immunization is still a very cheap intervention, considering the economic Impact of immunopreventable diseases in the society. The relative low cost of immunization throughout life makes this health inter-vention useful and worthwhile.(AU)

Neuron-glia interaction at the receptor level affects olfactory perception in adult Drosophila.

Some types of glia play an active role in neuronal signaling by modifying their activity although little is known about their role in sensory information signaling at the receptor level. In this research, we report a functional role for the glia that surround the soma of the olfactory receptor neurons (OSNs) in adult Drosophila. Specific genetic modifications have been targeted to this cell type to obtain live individuals who are tested for olfactory preference and display changes both increasing and reducing sensitivity. A closer look at the antenna by Ca2+ imaging shows that odor activates the OSNs, which subsequently produce an opposite and smaller effect in the glia that partially counterbalances neuronal activation. Therefore, these glia may play a dual role in preventing excessive activation of the OSNs at high odorant concentrations and tuning the chemosensory window for the individual according to the network structure in the receptor organ.

[Updated cost of vaccinating throughout life in Spain in 2023]. / Actualización del coste de vacunar a lo largo de toda la vida en España para el año 2023.

OBJECTIVE: Four modifications were introduced in the Lifetime Vaccination Schedule of the Interterritorial Council of the National Health System (CISNS) in 2023.The aim of this study was to estimate the cost of vaccinating a healthy person and people with certain risk conditions throughout life in Spain and to compare with a previous estimation from 2019. METHODS: A descriptive study of the cost of administering the vaccines included in the Lifetime Vaccination Schedule for the year 2023 and in the schedule for risk groups was carried out. RESULTS: The estimated cost to immunize a healthy person throughout life in 2023 is 1,541.56€ for a woman and 1,498.18€ for a men, which corresponds to an increase of 125% compared to the cost in 2019. The risk conditions with the highest cost are asplenia and complement deficiency and primary immunodeficiencies, with a cost of 3,159.82 euros and 2,566 euros respectively on average. The cost of vaccinating the whole healthy population in Spain in a year is around 565M€. Moreover, the cost of vaccinating the new-borns cohort of 2023 was estimated at 500M€. CONCLUSIONS: Despite the cost increase in 2023, immunization is still a very cheap intervention, considering the economic impact of immunopreventable diseases in the society. The relative low cost of immunization throughout life makes this health intervention useful and worthwhile.

OBJECTIVE: En el calendario de vacunación a lo largo de toda la vida del Consejo Interterritorial del Sistema Nacional de Salud (CISNS) se introdujeron cuatro modificaciones importantes en 2023. El objetivo de este estudio fue estimar el coste de la vacunación a lo largo de toda la vida a una persona sana y a ciertos grupos de riesgo tomando como referencia el calendario de 2023 y compararlo con una estimación previa de 2019. METHODS: Se realizo un estudio descriptivo del coste de administrar las vacunas incluidas en el calendario de vacunación a lo largo de toda la vida para el año 2023 y en el calendario para grupos de riesgo. RESULTS: El coste estimado de vacunar a una persona sana a lo largo de toda la vida en 2023 es de 1.541,56 euros en mujeres y 1.498,18 euros en hombres, lo que supondría un incremento del 125% con respecto al coste en 2019. Las condiciones de riesgo con el coste más alto son asplenia además de déficit del complemento e inmunodeficiencias primarias, suponiendo 3.159.82 euros y 2.566 euros, respectivamente, de media. Vacunar a toda la población sana en España en un año costaría unos 565 millones de euros y vacunar a la cohorte de recién nacidos de 2023 a lo largo de toda la vida unos 500 millones de euros. CONCLUSIONS: A pesar del incremento en el coste en 2023, considerando el impacto económico de las enfermedades prevenibles por vacunación en la sociedad, la vacunación sigue siendo una intervención barata que aporta múltiples beneficios.

The Ntan1 gene is expressed in perineural glia and neurons of adult Drosophila.

The Drosophila Ntan1 gene encodes an N-terminal asparagine amidohydrolase that we show is highly conserved throughout evolution. Protein isoforms share more than 72% of similarity with their human counterparts. At the cellular level, this gene regulates the type of glial cell growth in Drosophila larvae by its different expression levels. The Drosophila Ntan1 gene has 4 transcripts that encode 2 protein isoforms. Here we describe that although this gene is expressed at all developmental stages and adult organs tested (eye, antennae and brain) there are some transcript-dependent specificities. Therefore, both quantitative and qualitative cues could account for gene function. However, widespread developmental stage and organ-dependent expression could be masking cell-specific constraints that can be explored in Drosophila by using Gal4 drivers. We report a new genetic driver within this gene, Mz317-Gal4, that recapitulates the Ntan1 gene expression pattern in adults. It shows specific expression for perineural glia in the olfactory organs but mixed expression with some neurons in the adult brain. Memory and social behavior disturbances in mice and cancer and schizophrenia in humans have been linked to the Ntan1 gene. Therefore, these new tools in Drosophila may contribute to our understanding of the cellular basis of these alterations.

Validation of an Optogenetic Approach to the Study of Olfactory Behavior in the T-Maze of Drosophila melanogaster Adults.

Optogenetics enables the alteration of neural activity using genetically targeted expression of light activated proteins for studying behavioral circuits in several species including Drosophila. The main idea behind this approach is to replace the native behavioral stimulus by the light-induced electrical activation of different points of the circuit. Therefore, its effects on subsequent steps of the circuit or on the final behavior can be analyzed. However, the use of optogenetics to dissect the receptor elements of the adult olfactory behavior presents a challenge due to one additional factor: Most odorants elicit attraction or avoidance depending on their concentration; this complicates the representative replacement of odor activation of olfactory sensory neurons (OSNs) by light. Here, we explore a dual excitation model where the subject is responding to odors while the OSNs are optogenetically activated. Thereby, we can assess if and how the olfactory behavior is modified. We measure the effects of light excitation on the response to several odorant concentrations. The dose-response curve of these flies still depends on odor concentration but with reduced sensitivity compared to olfactory stimulation alone. These results are consistent with behavioral tests performed with a background odor and suggest an additive effect of light and odor excitation on OSNs.

[Committee for Immunization Programme and Registry and changes in the National Immunization Programme in Spain]. / Ponencia de Programa y Registro de Vacunaciones y evolución del calendario de vacunación en España.

The Committee for Immunization Programme and Registry (Ponencia de Programa y Registro de Vacunaciones) was created in 1991 to advise the Interterritorial Council of the National Health System on the situation of vaccine preventable diseases and the establishment and evaluation of measures for their prevention and control. Among other functions, this Committee evaluates the immunization programmes taking into account the scientific evidence and the epidemiological situation. In this way the Committee advises decision makers on the Public Health Commission of the Interterritorial Council. Any change in the National Immunization Programme, since the first one published in 1996 by the Interterritorial Council to the current Immunization Programme throughout life, has been advised from the technical and scientific point of view by this Committee. Taking into account both the work developed and the methodology used for developing the technical advice, the Committee for Immunization Programme and Registry is considered the National Immunization Technical Advisory Group for Spain. This paper reviews the functions and work developed by the Committee for Immunization Programme and Registry, the changes conducted in the National Immunization Programme under its advice and the current challenges.

La Ponencia de Programa y Registro de Vacunaciones se creó en 1991 para asesorar al Consejo Interterritorial del Sistema Nacional de Salud en el conocimiento de las enfermedades inmunoprevenibles y el establecimiento y evaluación de medidas para su prevención y control. Entre otras funciones, la Ponencia evalúa los programas de vacunación teniendo en cuenta la evidencia científica y la situación epidemiológica. De esta manera, asesora en la toma de decisiones que se realiza en la Comisión de Salud Pública del Consejo Interterritorial. Desde su creación, la Ponencia ha realizado recomendaciones desde el punto de vista técnico y científico en las modificaciones que se han realizado en el calendario de vacunación, incluyendo la incorporación de vacunas y el cambio de pautas de vacunación, desde el primer calendario del Consejo Interterritorial de 1996 hasta el actual calendario común de vacunación a lo largo de toda la vida. La Ponencia es considerada el Comité Técnico Asesor de Vacunaciones de España, tanto por las funciones que desarrolla como por la metodología utilizada para la elaboración de propuestas. En este artículo se revisan las funciones que desarrolla la Ponencia de Programa y Registro de Vacunaciones, las modificaciones que se han realizado en el calendario con su asesoramiento y los retos en el momento actual.

[The cost of vaccination throughout life in Spain]. / El coste de vacunar a lo largo de toda la vida en España.

OBJECTIVE: The evaluation of vaccination programmes using cost estimation is an essential tool for immunization policy. The aim of this study was to describe the cost of vaccination through-out life in Spain, both in healthy and risk groups persons. METHODS: Description of cost of vaccination following the national immunization programme throughout life agreed for 2019, and the immunization programme for risk groups. RESULTS: The expected cost to immunize a healthy person is 726.06 euros for a healthy woman and 625.89 euros for a healthy man, ranging from 982.99 to 1,815 euros per person in risk groups. CONCLUSIONS: The relatively low cost and the important benefits for health of immunization throughout life make this public health measure useful and worthwhile. Evaluation of immunization programmes should be strengthened in order to assure suitable immunization in every stage of life.

OBJETIVO: La evaluación de los programas de vacunación mediante la estimación de costes es una herramienta fundamental para orientar la política de vacunación. El objetivo de este trabajo fue describir el coste que conlleva en España la vacunación a lo largo de toda la vida, tanto a personas sanas como pertenecientes a grupos de riesgo. METODOS: Se realizó un estudio de descripción de los costes para administrar las vacunas incluidas en el calendario común de vacunación acordado para el año 2019, y en el calendario para grupos de riesgo, a lo largo de toda la vida. RESULTADOS: El coste previsto de la vacunación a lo largo de toda la vida fue de 726,06 euros por cada mujer sana y 625,89 euros por cada hombre sano durante el 2019. En personas con las condiciones de riesgo que requieren mayor número de vacunas osciló entre 982,99 y 1.815 euros por persona. CONCLUSIONES: El relativo bajo coste de la vacunación a lo largo de toda la vida y los importantes beneficios para la salud que conlleva la vacunación hacen que esta medida sea útil y rentable, por lo que se debe reforzar la evaluación de los programas de vacunación para asegurar la vacunación adecuada en todos los momentos de la vida.

Ponencia de Programa y Registro de Vacunaciones y evolución del Calendario de Vacunación en España / Committee for Immunization Programme and Registry and changes in the National Immunization Programme in Spain

La Ponencia de Programa y Registro de Vacunaciones se creó en 1991 para asesorar al Consejo Interterritorial del Sistema Nacional de Salud en el conocimiento de las enfermedades inmunoprevenibles y el establecimiento y evaluación de medidas para su prevención y control. Entre otras funciones, la Ponencia evalúa los programas de vacunación teniendo en cuenta la evidencia científica y la situación epidemiológica. De esta manera, asesora en la toma de decisiones que se realiza en la Comisión de Salud Pública del Consejo Interterritorial. Desde su creación, la Ponencia ha realizado recomendaciones desde el punto de vista técnico y científico en las modificaciones que se han realizado en el calendario de vacunación, incluyendo la incorporación de vacunas y el cambio de pautas de vacunación, desde el primer calendario del Consejo Interterritorial de 1996 hasta el actual calendario común de vacunación a lo largo de toda la vida. La Ponencia es considerada el Comité Técnico Asesor de Vacunaciones de España, tanto por las funciones que desarrolla como por la metodología utilizada para la elaboración de propuestas. En este artículo se revisan las funciones que desarrolla la Ponencia de Programa y Registro de Vacunaciones, las modificaciones que se han realizado en el calendario con su asesoramiento y los retos en el momento actual

The Committee for Immunization Programme and Registry (Ponencia de Programa y Registro de Vacunaciones) was created in 1991 to advise the Interterritorial Council of the National Health System on the situation of vaccine preventable diseases and the establishment and evaluation of measures for their prevention and control. Among other functions, this Committee evaluates the immunization programmes taking into account the scientific evidence and the epidemiological situation. In this way the Committee advises decision makers on the Public Health Commission of the Interterritorial Council. Any change in the National Immunization Programme, since the first one published in 1996 by the Interterritorial Council to the current Immunization Programme throughout life, has been advised from the technical and scientific point of view by this Committee. Taking into account both the work developed and the methodology used for developing the technical advice, the Committee for Immunization Programme and Registry is considered the National Immunization Technical Advisory Group for Spain. This paper reviews the functions and work developed by the Committee for Immunization Programme and Registry, the changes conducted in the National Immunization Programme under its advice and the current challenges

El coste de vacunar a lo largo de toda la vida en España / The cost of vaccination throughout life in Spain

OBJETIVO: La evaluación de los programas de vacunación mediante la estimación de costes es una herramienta fundamental para orientar la política de vacunación. El objetivo de este trabajo fue describir el coste que conlleva en España la vacunación a lo largo de toda la vida, tanto a personas sanas como pertenecientes a grupos de riesgo. METODOS: Se realizó un estudio de descripción de los costes para administrar las vacunas incluidas en el calendario común de vacunación acordado para el año 2019, y en el calendario para grupos de riesgo, a lo largo de toda la vida. RESULTADOS: El coste previsto de la vacunación a lo largo de toda la vida fue de 726,06 euros por cada mujer sana y 625,89 euros por cada hombre sano durante el 2019. En personas con las condiciones de riesgo que requieren mayor número de vacunas osciló entre 982,99 y 1.815 euros por persona. CONCLUSIONES: El relativo bajo coste de la vacunación a lo largo de toda la vida y los importantes beneficios para la salud que conlleva la vacunación hacen que esta medida sea útil y rentable, por lo que se debe reforzar la evaluación de los programas de vacunación para asegurar la vacunación adecuada en todos los momentos de la vida

OBJECTIVE: The evaluation of vaccination programmes using cost estimation is an essential tool for immunization policy. The aim of this study was to describe the cost of vaccination through-out life in Spain, both in healthy and risk groups persons. METHODS: Description of cost of vaccination following the national immunization programme throughout life agreed for 2019, and the immunization programme for risk groups. RESULTS: The expected cost to immunize a healthy person is 726.06 euros for a healthy woman and 625.89 euros for a healthy man, ranging from 982.99 to 1,815 euros per person in risk groups. CONCLUSIONS: The relatively low cost and the important benefits for health of immunization throughout life make this public health measure useful and worthwhile. Evaluation of immunization programmes should be strengthened in order to assure suitable immunization in every stage of life

Campaña de vacunación frente a la gripe 2020-2021: este año más que nunca, vacunándonos marcamos la diferencia / No disponible

No disponible

[Methodology of the 2nd seroprevalence study in Spain]. / Metodología del 2º estudio de seroprevalencia en España.

Seroprevalence studies are designed in population samples to assess the level and distribution of immunity induced by natural infection of certain infectious agents or by immunization against them. The purpose of the 2nd Seroprevalence Study in Spain is to assess the prevalence and distribution of immune status against vaccine-preventable diseases and generated by natural infection by other microorganisms. Pathologies specifically included in the study are: poliomyelitis, diphtheria, tetanus, pertussis, measles, rubella, mumps, varicella, invasive meningococcal disease by serogroup C, hepatitis A, hepatitis B, hepatitis E, hepatitis C and HIV. The study has a similar design of that conducted in 1996, as it is a descriptive cross-sectional study in resident population of 2 to 80 years of age in Spain. Two-stage conglomerate sampling was carried out on the population aged 2 to 80 years living in Spain, with an initial sample size of 10,000 people. The methodology of the study is described in this article.

Los estudios de seroprevalencia se elaboran en muestras poblacionales con el fin de investigar el nivel y distribución de la inmunidad inducida por infección natural de determinados agentes infecciosos o por vacunación frente a los mismos. El 2º Estudio de Seroprevalencia en España tiene el objetivo de estimar la prevalencia y distribución del estado inmune frente a las enfermedades inmunoprevenibles y de la generada por infección natural por otros microrganismos. En concreto, las patologías incluidas en el estudio son: poliomielitis, difteria, tétanos, tosferina, sarampión, rubéola, parotiditis, varicela, enfermedad meningocócica invasora por serogrupo C, hepatitis A, hepatitis B, hepatitis C, hepatitis E e infección por virus de la inmunodeficiencia humana (VIH). Para ello, se ha diseñado un estudio similar al realizado en 1996, observacional de tipo transversal en la población residente en España de 2 a 80 años de edad. Se ha realizado un muestreo por conglomerados bietápico de la población de 2 a 80 años residente en España, con un tamaño muestral inicial de 10.000 personas. En este artículo se describe la metodología utilizada en la realización del estudio.

Características y evolución de la insuficiencia cardiaca con función sistólica recuperada en un hospital no terciario / Long-term and clinical profile of heart failure with recovered ejection fraction in a non-tertiary hospital

Introducción: La insuficiencia cardiaca (IC) con fracción de eyección (FE) recuperada está emergiendo como un subtipo de IC diferenciada. Existe poca información sobre su perfil clínico en centros que no son referencia. Métodos: Analizamos la evolución y pronóstico de los pacientes afectos de IC con FE recuperada seguidos prospectivamente en una unidad de IC de un hospital no terciario. Resultados: Se ha seguido a 431 pacientes con FE deprimida (mediana 50 meses; edad media de 70,3±12,2 años; el 79,3% eran varones.) El 26,9% normalizaron la FEVI; el 76,7% de ellos en el primer año. Comparados con los pacientes que no normalizaron la FEVI, eran más jóvenes, el origen isquémico de la IC era menos frecuente y presentaban menos comorbilidad. Su pronóstico es mejor (mediana de supervivencia 85,2± 2,1vs. 74,2± 1,9 meses, log-rank χ2 11,5; p = 0,001; hazard ratio de 0,37, intervalo de confianza [IC] del 95%: 0,21-0,67; p = 0,002). Las causas de muerte principalmente no estaban relacionadas con IC. Las variables predictoras de normalización de la FEVI fueron la edad (odds ratio [OR] para más de 69 años 0,98; IC 95%: 0,96-0,99; p = 0,025), origen no isquémico (OR 1,12; IC 95%: 1,01-1,21; p = 0,003) y prescripción de antialdosterónicos (OR 1,89; IC 95%: 1,05-3,26; p = 0,023). Conclusión: La normalización de la FE en pacientes con IC con FE reducida es frecuente y presenta unas características basales, evolución y pronóstico más favorables que la IC con persistencia de FE reducida. Investigaciones futuras deberán confirmar su historia natural y tratamiento óptimo

Introduction: Heart failure (HF) with recovered ejection fraction (EF) is emerging as a different HF subtype. There is little information about his clinical profile in hospitals that are not a reference. Methods: We analysed characteristics and prognosis in patients with recovered HF followed prospectively in the HF Unit of a non-tertiary hospital. Results: A total of 431 patients with HF with reduced EF were followed (median 50 months, 79.3% males, mean age 70.3±12.2years). Of the patients, 26.9% (N 116) recovered EF, mainly in the first year of follow-up (76.7%). Compared with patients that did not recovered EF in the follow-up, they were younger, rate of ischemic origin of cardiomyopathy was less frequent and presented less comorbidity. Mortality was lower in patients with recovered HF (survival median of 85.2±2.1 vs. 74.2±1.9 months [log-rank χ2 11.5, P=0.001], hazard ratio 0.37, 95% confidence interval [CI]: 0.21-0.67, P=0.002). Aetiology of deaths was not mainly secondary to HF. Younger age of 68 years (odds ratio [OR] 0-98, 95% CI: 0.96-0,99; P=0.025), ischemic origin (OR 1.12, 95% CI: 1.01-1.21; P=0.003) and use of aldosterone antagonists (OR 1.89, 95% CI: 1.09-3.26; P=0.023) were the variables independently associated to normalisation of EF. Conclusion: HF with recovered EF is a frequent phenomenon. It has a more favourable clinical course, prognosis and basal characteristics than HF with persistent reduced EF. Further studies are needed to identify natural history and optimal medications for HF-recovered patients

Long-term and clinical profile of heart failure with recovered ejection fraction in a non-tertiary hospital. / Características y evolución de la insuficiencia cardiaca con función sistólica recuperada en un hospital no terciario.

INTRODUCTION: Heart failure (HF) with recovered ejection fraction (EF) is emerging as a different HF subtype. There is little information about his clinical profile in hospitals that are not a reference. METHODS: We analysed characteristics and prognosis in patients with recovered HF followed prospectively in the HF Unit of a non-tertiary hospital. RESULTS: A total of 431 patients with HF with reduced EF were followed (median 50 months, 79.3% males, mean age 70.3±12.2years). Of the patients, 26.9% (N 116) recovered EF, mainly in the first year of follow-up (76.7%). Compared with patients that did not recovered EF in the follow-up, they were younger, rate of ischemic origin of cardiomyopathy was less frequent and presented less comorbidity. Mortality was lower in patients with recovered HF (survival median of 85.2±2.1 vs. 74.2±1.9 months [log-rank χ2 11.5, P=0.001], hazard ratio 0.37, 95% confidence interval [CI]: 0.21-0.67, P=0.002). Aetiology of deaths was not mainly secondary to HF. Younger age of 68 years (odds ratio [OR] 0-98, 95% CI: 0.96-0,99; P=0.025), ischemic origin (OR 1.12, 95% CI: 1.01-1.21; P=0.003) and use of aldosterone antagonists (OR 1.89, 95% CI: 1.09-3.26; P=0.023) were the variables independently associated to normalisation of EF. CONCLUSION: HF with recovered EF is a frequent phenomenon. It has a more favourable clinical course, prognosis and basal characteristics than HF with persistent reduced EF. Further studies are needed to identify natural history and optimal medications for HF-recovered patients.

Metodología del 2º estudio de seroprevalencia en España / Methodology of the 2nd seroprevalence study in Spain

Los estudios de seroprevalencia se realizan sobre una muestra de problación con el fin de investigar el nivel y distribución de la inmunidad inducida por infección natural de determinados agentes infecciosos o por vacunación frente a los mismos. El 2º Estudio de Seroprevalencia en España tiene el objetivo de estimar la prevalencia y distribución del estado inmune frente a las enfermedades inmunoprevenibles y de la generada por infección natural por otros microrganismos. En concreto, las patologías incluidas en el estudio son: poliomielitis, difteria, tétanos, tosferina, sarampión, rubéola, parotiditis, varicela, enfermedad meningocócica invasora por serogrupo C, hepatitis A, hepatitis B, hepatitis C, hepatitis E e infección por virus de la inmunodeficiencia humana (VIH). Para ello, se ha diseñado un estudio similar al realizado en 1996, observacional de tipo transversal en la población residente en España de 2 a 80 años de edad. Se ha realizado un muestreo por conglomerados bietápico de la población de 2 a 80 años residente en España, con un tamaño muestral inicial de 10.000 personas. En este artículo se describe la metodología utilizada en la realización del estudio

Seroprevalence studies are designed in population samples to assess the level and distribution of immunity induced by natural infection of certain infectious agents or by immunization against them. The purpose of the 2nd Seroprevalence Study in Spain is to assess the prevalence and distribution of immune status against vaccine-preventable diseases and generated by natural infection by other microorganisms. Pathologies specifically included in the study are: poliomyelitis, diphtheria, tetanus, pertussis, measles, rubella, mumps, varicella, invasive meningococcal disease by serogroup C, hepatitis A, hepatitis B, hepatitis E, hepatitis C and HIV. The study has a similar design of that conducted in1996, as it is a descriptive crosssectional study in resident population of 2 to 80 years of age in Spain. Two-stage conglomerate sampling was carried out on the population aged 2 to 80 years living in Spain, with an initial sample size of 10,000 people. The methodology of the study is described in this article

Semana Europea de la Vacunación (del 22 al 28 de abril de 2019) / No disponible

No disponible

Health system factors influencing management of multidrug-resistant tuberculosis in four European Union countries - learning from country experiences.

BACKGROUND: In the European Union and European Economic Area only 38% of multidrug-resistant tuberculosis patients notified in 2011 completed treatment successfully at 24 months' evaluation. Socio-economic factors and patient factors such as demographic characteristics, behaviour and attitudes are associated with treatment outcomes. Characteristics of healthcare systems also affect health outcomes. This study was conducted to identify and better understand the contribution of health system components to successful treatment of multidrug-resistant tuberculosis. METHODS: We selected four European Union countries to provide for a broad range of geographical locations and levels of treatment success rates of the multidrug-resistant tuberculosis cohort in 2009. We conducted semi-structured interviews following a conceptual framework with representatives from policy and planning authorities, healthcare providers and civil society organisations. Responses were organised according to the six building blocks of the World Health Organization health systems framework. RESULTS: In the four included countries, Austria, Bulgaria, Spain, and the United Kingdom, the following healthcare system factors were perceived as key to achieving good treatment results for patients with multidrug-resistant tuberculosis: timely diagnosis of drug-resistant tuberculosis; financial systems that ensure access to a full course of treatment and support for multidrug-resistant tuberculosis patients; patient-centred approaches with strong intersectoral collaboration that address patients' emotional and social needs; motivated and dedicated healthcare workers with sufficient mandate and means to support patients; and cross-border management of multidrug-resistant tuberculosis to secure continuum of care between countries. CONCLUSION: We suggest that the following actions may improve the success of treatment for multidrug-resistant tuberculosis patients: deployment of rapid molecular diagnostic tests; development of context-specific treatment guidance and criteria for hospital admission and discharge in the European context; strengthening patient-centred approaches; development of collaborative mechanisms to ensure cross-border care, and development of long-term sustainable financing strategies.

Early improvement of the regional and global ventricle function estimated by two-dimensional speckle tracking echocardiography after percutaneous aortic valve implantation speckle tracking after CoreValve implantation.

BACKGROUND: To assess changes in myocardial deformation and ejection fraction (EF) by two-dimensional speckle tracking echocardiography (2DSTE) after transcatheter aortic valve implantation (TAVI). METHODS: A total of 24 patients (50% males, age 78 ± 4 years) were selected for TAVI because of severe aortic stenosis. A comprehensive echocardiographic study was performed before TAVI, at discharge, and after 1-month follow-up. EF was assessed by 2D conventional echocardiography with Simpson method and by 2DSTE. Radial and circumferential strains were evaluated in six segments in the short-axis view at the level of the papillary muscles, and longitudinal strain in six segments in the four-chamber apical view, by means of 2DSTE. All studies were performed with an iE-33 echocardiography device (Philips). RESULTS: At discharge, the mean EF estimated by 2DSTE improved significantly when compared with the basal one (56 ± 7% vs. 51 ± 8%, P < 0.01), while EF by Simpson method did not change (67 ± 9% vs. 64 ± 16%, P = 0.2). At that time, global radial (21.4 ± 9% vs. 11.5 ± 7.6%, P = 0.000), circumferential (-20.7 ± 8% vs. -15.2 ± 7%, P = 0.02), and longitudinal strains (-14.8 ± 6.2% vs. -12 ± 6%, P = 0.02) improved significantly when compared with the basal one. At 1-month follow-up, global radial (20.1 ± 5.6% vs. 21.4 ± 9%, P = 0.88) and circumferential (-20 ± 8% vs. -20.7 ± 8%, P = 0.35) strains did not vary and a new significant improvement was observed in longitudinal global strain (-19.2 ± 6.5% vs. -14.8 ± 6.2%, P = 0.002). CONCLUSIONS: A new echocardiographic technique, such as 2DSTE, shows a significant early improvement in global and segmental left ventricular systolic function after TAVI, which could not be detected by conventional methods.

Manejo terapéutico del paciente con arteriopatía no coronaria (enfermedad arterial periférica y/o enfermedad cerebrovascular): más allá de los síntomas / The management of patients with con coronary arterial disease (peripheral arterial disease or cerebrovascular disease). Going beyond symptoms

La aterosclerosis es un proceso difuso que afecta a diversas localizaciones vasculares y da lugar a las manifestaciones clínicas de la cardiopatía isquémica, la arteriopatía periférica y la enfermedad cerebrovascular. Aunque con pequeños matices, los factores de riesgo y la etiopatogenia son comunes a todas ellas, por lo que su tratamiento y su prevención se basan en el control de los factores de riesgo y en el uso de antiagregantes, IECA o ARA-II y estatinas, junto con otras medidas específicas de cada enfermedad. Se revisan los efectos beneficiosos de estos tratamientos, así como las indicaciones de revascularización, bien mediante cirugía, bien mediante angioplastia percutánea con stents, en la enfermedad cerebrovascular y la enfermedad arterial de las extremidades inferiores (AU)

Atherosclerosis is a widespread disease process that affects a range of different vascular territories and which gives rise to the clinical manifestations of ischemic heart disease, peripheral arterial disease and cerebrovascular disease. Although the details differ slightly, these conditions all share the same risk factors and pathogenesis. Consequently, their prevention and treatment are based on the control of these common risk factor and involve the use of antiplatelet agents, angiotensin-converting enzyme inhibitors or angiotensin-II receptor antagonists, and statins combined with other measures particular to each condition. This article reviews the beneficial effects of these therapies and discusses indications for revascularization, whether through surgery or percutaneous angioplasty with stents, in cerebrovascular disease and peripheral arterial disease of the lower extremities (AU)